PEPTONIC medical AB (XSAT:PMED) Cyclically Adjusted PS Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PEPTONIC medical AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PEPTONIC medical AB  (XSAT:PMED) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


PEPTONIC medical AB Cyclically Adjusted PS Ratio Related Terms


PEPTONIC medical AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for PEPTONIC medical AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PEPTONIC medical AB Cyclically Adjusted PS Ratio Chart

PEPTONIC medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.77 0.07 0.00

PEPTONIC medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSAT:PMED vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PEPTONIC medical AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PEPTONIC medical AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PEPTONIC medical AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PEPTONIC medical AB's Cyclically Adjusted PS Ratio falls into.



PEPTONIC medical AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

PEPTONIC medical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, PEPTONIC medical AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/133.5600*133.5600
=0.000

Current CPI (Mar. 2026) = 133.5600.

PEPTONIC medical AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.000 103.279 0.000
201712 0.000 103.793 0.000
201803 0.000 103.962 0.000
201806 0.000 104.875 0.000
201809 0.000 105.679 0.000
201812 0.001 105.912 0.001
201903 0.006 105.886 0.008
201906 0.004 106.742 0.005
201909 0.004 107.214 0.005
201912 0.001 107.766 0.001
202003 0.005 106.563 0.006
202006 0.003 107.498 0.004
202009 0.020 107.635 0.025
202012 0.015 108.296 0.018
202103 0.020 108.360 0.025
202106 0.015 108.928 0.018
202109 0.014 110.338 0.017
202112 0.011 112.486 0.013
202203 0.018 114.825 0.021
202206 0.019 118.384 0.021
202209 0.019 122.296 0.021
202212 0.016 126.365 0.017
202303 0.005 127.042 0.005
202306 0.007 129.407 0.007
202309 0.006 130.224 0.006
202312 0.003 131.912 0.003
202403 0.006 132.205 0.006
202406 0.003 132.716 0.003
202409 0.001 132.304 0.001
202412 0.001 132.987 0.001
202503 0.000 132.825 0.000
202506 0.000 133.699 0.000
202509 0.000 133.480 0.000
202512 0.000 133.390 0.000
202603 0.000 133.560 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PEPTONIC medical AB Business Description

Address Gustavslundsvagen 143, Bromma, SWE, SE-167 51
PEPTONIC medical AB is a pharmaceutical company. It is engaged in developing oxytocin-based products for the treatment of menopausal symptoms, such as vaginal atrophy and vaginal dryness. Oxytocin is for medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. The company is based in Sweden.